N/A N=104 Randomized Treatment

Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens

Cataract

Bottom Line

View on ClinicalTrials.gov: NCT00762021 ↗

Enrolled (actual)

104

Serious AEs

0.0%

Results posted

Dec 2010

Primary outcome: Primary: Posterior Capsule Opacification (PCO) — 11.58; 14.04 Percentage of PCO

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: SN60AT (Device); SN60WF (Device)
Age: Adult, Older Adult · 50+ yrs
Sex: All
Sponsor: Alcon Research
Primary completion: Aug 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY Posterior Capsule Opacification (PCO)	11.58; 14.04	—
PRIMARY 100% LogMAR Best Corrected Visual Acuity (BCVA)	0.04; 0.07	—
PRIMARY 9% LogMAR Best Corrected Visual Acuity (BCVA)	0.42; 0.45	—

Summary

To assess posterior capsule opacification (PCO) in patients implanted with either the AcrySof SN60AT lens or the AcrySof SN60WF lens.

Eligibility Criteria

Inclusion Criteria

patients with bilateral senile cataracts
Age > 50 years
Fit for hospital follow ups
Pupils dilating > 6mm preoperatively
Eyes expected to see 6/12 or better postoperatively

Exclusion Criteria

Diabetes
On treatment for glaucoma
Other ocular pathology
Previous ocular surgery

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00762021). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.